-

Agilent Names Bret DiMarco Chief Legal Officer

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced Bret DiMarco has been named to lead the company’s global legal organization as senior vice president and chief legal officer, as well as serving as secretary. He begins his new role with Agilent effective today.

“Bret DiMarco is another outstanding addition to the Agilent leadership team,” said Padraig McDonnell, Agilent president and CEO. “Bret’s broad range of tactical and strategic experience across a variety of industries will be valuable assets as our company becomes even more customer focused and even more nimble to continue to win in the marketplace and add value to customers and shareholders.”

Most recently, DiMarco served as chief legal officer of Pendo.io, a leading global venture-backed software-as-a-service (SaaS) company. Before joining Pendo.io, he was executive vice president, chief legal officer, and corporate secretary for Coherent Inc., a multinational corporation and one of the world’s largest laser manufacturers. There, he was responsible for all legal matters, the company’s intellectual property program and global trade compliance. After leading the process for the sale and closing of the company’s merger with II-VI Incorporated, he served as a special adviser to the company president during the initial transition period.

DiMarco previously was an associate and member of the international law firm Wilson Sonsini Goodrich & Rosati, where his practice focused on corporate and securities law, corporate governance and mergers and acquisitions. DiMarco also has served on multiple Nasdaq councils, currently as the chair of the Nasdaq Exchange Nominating Committee. He has been an adjunct assistant professor of law at the University of California Law School, San Francisco since 2004.

DiMarco is a graduate of the University of Southern California Law School and received his bachelor’s degree from the University of California, Irvine.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact:
Sarah Litton
+1 408-361-0405
sarah.litton@agilent.com

Investor Contact:
Parmeet Ahuja
+1 408-345-8948
parmeet_ahuja@agilent.com

AGILENT TECHNOLOGIES INC

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Media Contact:
Sarah Litton
+1 408-361-0405
sarah.litton@agilent.com

Investor Contact:
Parmeet Ahuja
+1 408-345-8948
parmeet_ahuja@agilent.com

Social Media Profiles
More News From AGILENT TECHNOLOGIES INC

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise a...

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025

SANTA CLARA, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will...

Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Columbia University has received an Agilent Research Catalyst (ARC) Award on behalf of Dr. Pawel Muranski, an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Med...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.